6%, BOC: 59.4%, p>0.05). Ribavirin plasma concentration was not a predictive factor of RVR (1.87 ± 0.91 mg/L vs 1.96 selleckchem ± 0.72 mg/L, respectively in RVR and in non RVR patients, p=0.65). In multivariate analysis, only the Fibroscan® value was a predictive factor of SVR with a cutoff value below 20 KPa. Anemia (hemoglobin
level <12 g/dL) occured in 56 of the 66 patients (85%). A significant correlation (p=0.0006) was found between hemoglobin level and ribavirin plasma concentration. Anemia was more frequent when the ribavirin plasma concentration was above the cutoff value of 1.65 mg/L (p=0.04). The decrease of the creatinine clearance after 4 weeks of protease inhibitor was more important in patients treated with TPV (26.51 mL/min) than in patients treated by BOC (4.17 mL/min), p<0.05. The logistic regression Wnt inhibitor analysis showed a significant correlation between a high ribavirin concentration and a decrease of creatinine clearance (p=0.0157). Conclusion: In combination therapy with telaprevir or bocepre-vir, rapid or sustained virological response was not influenced by ribavirin plasma concentration. However, plasma ribavirin level was a predictive factor associated to anemia and kidney function impairment during therapy. Disclosures: Laurent Alric – Grant/Research Support: Roche, MSD, BMS, Gilead The following people have nothing to disclose: Marie Julia, Peggy Gandia, Mathieu Guivarch, Laura Coimet-Berger, Florence Abravanel, Delphine
Bonnet Background: Real life data of triple based therapy in patients with chronic hepatitis C are investigated in this multicentric survey of 11 clinical centers
of South Italy. This is a retrospective study analyzing data from 176 consecutive patients fol-lowed-up for a maximum of 12 weeks after the end of therapy (EOT). Patients and Methods: One hundred and twenty-five (70%) patients were treated with telaprevir and 51 (30%) with boceprevir. No differences were found in the two groups for the principal demographic characteristics. selleck The degree of liver fibrosis (LF) was done according to liver biopsy (LB) and/or transient elastography (TE). Patients with evidence of clinical signs of liver cirrhosis (LC) (ie. esophageal varices) did not undergo neither LB or TE. Fifthy-three/ 176 patients (30%) had liver cirrhosis. Sixteen patients (9%) were naïve and all the remaining were experienced patients: 92 non responders ( 52,84%); 63 relapsers (35,79%) and 5 drop-out (2,8%). Uni-variate and multivariate analysis were performed according to SPSS program. Results: The rate of rapid virological response (RVR) and EOT, analyzed on all patients were the following: 116 (68%) and 94 (75.8%). Ninety-seven patients have been followed-up for at least 12 weeks after the EOT and of these 61 (62.9%) achieved sustained virological response (SVR). The multivariate analysis for SVR, RVR is the only independent predictive factor of SVR irrespective of the degree of LF and the type of response to previous treatment.